| |
Approaching early development strategically is critical to the later success of a drug candidate. Discover the current challenges and considerations for biotechs to maximize drug development outcomes. +(2)+(2).png)
|
|
Today’s Big NewsJan 16, 2025 |
|
Wednesday, February 12, 2025 | 10am ET / 7am PT If you are a company developing advanced therapies, don’t miss this webinar to learn about packaging innovations and aseptic filling solutions that meet the demands of emerging therapies and ensure product integrity, safety and efficiency. 
|
|
| By Kevin Dunleavy After a run of court victories in a patent dispute with the U.S. government, Gilead has agreed to settle to resolve the feds’ last-ditch appeal. Terms of the deal were not disclosed in the case, which involved the government’s patents on Gilead’s HIV drugs Truvada and Descovy for pre-exposure prophylaxis. |
|
|
|
By Gabrielle Masson Boehringer Ingelheim’s investigational schizophrenia candidate has failed to improve cognitive impairment or functioning in a trio of late-stage trials. |
By Eric Sagonowsky The FDA has issued a complete response letter for Atara's biologics license application "solely related to inspection findings" at a third-party manufacturer, the biotech said. |
By Andrea Park AbbVie closed out the year on a high note, as its blockbuster biologic Skyrizi once again claimed the top spot in 2024’s final monthly ranking of the biggest TV ad spenders in biopharma. |
|
Wednesday, February 19, 2025 | 11am ET / 8am PT This webinar takes a deep dive into effective formulation strategies to overcome current solubility and bioavailability hurdles. Join us to explore the latest advancements in bioavailability enhancement technologies and critical factors for selecting the right formulation approach. Register now. 
|
|
By Angus Liu Although Bayer’s top-selling drug Xarelto lost market exclusivity in most geographies in 2024, the company still sees strong growth from the pharma business beginning in 2027. |
By Fraiser Kansteiner Among the myriad drugmakers laying out their plans for the future at this year’s J.P. Morgan Healthcare Conference, Takeda said it's laser-focused on six pipeline assets that could each reel in blockbuster-level sales down the line. |
By Ben Adams,Gabrielle Masson,Darren Incorvaia,James Waldron Welcome to day 3 of the J.P. Morgan Healthcare Conference in San Francisco. |
By Andrea Park Kite Pharma is flying high with the addition of a new member to its senior leadership team. Brian Heath has joined Gilead Sciences’ cell therapy subsidiary as a senior VP and head of global commercial, he announced on LinkedIn this week. |
By James Waldron Servier is extending its pact with Google Cloud as the French biopharma points to 60 examples of how generative artificial intelligence (gen AI) could improve its drug development processes. |
By Nick Paul Taylor Avacta is stepping up development of its peptide-drug conjugate, kicking off expansion cohorts in multiple tumor types after seeing one partial response in 10 salivary gland cancer patients. |
By Darren Incorvaia Serina Therapeutics is shedding a subsidiary to start the new year off debt-free. The Alabama-based biotech has sold UniverXome Bioengineering to clear away $11.2 million in debt. |
By Nick Paul Taylor Aileron Therapeutics pulled a hard pivot in 2023, merging with Lung Therapeutics to gain a new pipeline and investor base. Now, the biotech has distanced itself from its premerger form by rebranding as Rein Therapeutics. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” we dive into 2024's batch of new FDA drug approvals, highlighting some potential blockbusters and shifts from previous years' lists. |
|
|---|
|
|
Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter, strategic consultants in the life sciences |
| |
|
.+(1).png)
